Hospital Injectable Products · LP-193
Insulin soluble Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-193Hospital Injectable Products
- Generic identity
- Insulin solubleInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-193
- Generic ingredient
- Insulin soluble
- Dosage form
- Injection
- Proposed strength
- 100 IU/mL vial
- Proposed pack
- 10 mL vial; cold-chain carton
- Portfolio category
- Hospital Injectable Products
About Insulin soluble
Soluble insulin refers to a clear insulin preparation used in defined diabetes-care settings. It must be distinguished from NPH suspensions, premixed insulins and insulin analogues. The source does not fully specify insulin identity, so the final product record requires further pharmaceutical confirmation. A vial concentration does not establish all permitted routes or make different insulin products interchangeable.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical use is based on an individualized plan that accounts for glucose monitoring, meals, activity, other medicines and the treatment setting. Some soluble human-insulin products also have hospital uses under closely controlled protocols, but such routes and indications cannot be assumed for a candidate. This page supplies general educational context without a correction scale, emergency algorithm, administration timing or a product-switching instruction.
Important safety considerations
Hypoglycaemia, including severe episodes, is a principal risk. Wrong-insulin and wrong-concentration errors can cause serious harm, while inadequate delivery can lead to severe hyperglycaemia. Hypokalaemia and allergic reactions are additional concerns. Renal function, illness, changes in food intake and activity can alter management needs. Syringes and delivery devices must match the exact product. Never infer intravenous suitability from the word soluble alone.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The record describes a 100 IU/mL vial. Confirm the precise insulin identity, concentration convention, appearance, preservatives and authorized routes. Clear appearance does not by itself identify the insulin or establish equivalence with a different clear insulin product.
Use product-specific requirements for unopened storage, transport and time after first opening. Verify label, concentration, expiry and appearance before use. Do not transfer storage or compatibility limits from another insulin, and handle temperature excursions through an appropriate professional assessment.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm product identity, prescribed diabetes or hospital-care plan, monitoring and appropriate equipment. Verify any parenteral route against the actual authorized label.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Insulin soluble
- Dosage form / presentation
- Injection
- Catalogue strength
- 100 IU/mL vial
- Catalogue pack
- 10 mL vial; cold-chain carton
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- P022 — The catalogue says “Insulin soluble” at 100 IU/mL in a 10 mL vial, but it does not establish the exact insulin species/source, whether the product is recombinant human regular insulin, or the complete formulation.
- The external regular-human-insulin label is comparator context only. Clear appearance, “soluble” wording and 100 IU/mL do not establish route, interchangeability or exact identity.
- Approved indication, patient eligibility and dosing or test interpretation are not established by this portfolio record.
- Registration/authorization, manufacturing or site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: HUMULIN R (insulin human) injection — external comparatorgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled insulin master and finished-product specification confirming exact insulin identity/source, formulation type, concentration, excipients, vial closure, authorised route(s) and product-specific handling/storage.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-193, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-193.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.